NovoCure (NVCR) Gross Profit (2014 - 2026)

NovoCure (NVCR) has reported Gross Profit for 13 consecutive years, with $142.5 million the latest figure, recorded in Q2 2026.

• Quarterly Gross Profit rose 21.43% year-over-year to $142.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $532.3 million (up 10.58% YoY) and the FY2025 annual result came in at $488.5 million, up 4.37% from the prior year.
• Gross Profit advanced to $142.5 million in Q2 2026 per NVCR's latest filing, from $135.1 million in the prior quarter.
• Over the last five years, Gross Profit for NVCR reached as high as $142.5 million in Q2 2026 and fell as low as $92.0 million in Q2 2023.
• A 5-year average of $113.2 million and a median of $114.0 million in 2022 frame the typical range for Gross Profit.
• Annual changes were most pronounced in 2023 — Gross Profit dropped 18.09% — and 2024, when it climbed 26.25%.
• Year by year, Gross Profit stood at $99.5 million in 2022, then gained by 1.69% to $101.2 million in 2023, then advanced by 26.25% to $127.8 million in 2024, then increased by 3.44% to $132.2 million in 2025, then climbed by 7.78% to $142.5 million in 2026.
• According to Business Quant data, Gross Profit over the past three periods registered $142.5 million, $135.1 million, and $132.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.